{"DataElement":{"publicId":"2422285","version":"1","preferredName":"Phase II Trial Recommendation Agent Dose","preferredDefinition":"If known, provide the TAC (Treatment Assignment Codes) for the recommended Phase 2 dose or minimum effective dose for each subgroup as applicable. Determination of the recommended Phase 2 dose or minimum effective dose should be based on protocol criteria.","longName":"PH_II_TR_REC_AGT_DOS","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2422283","version":"1","preferredName":"Phase II Trial Recommendation","preferredDefinition":"An advised element in regards to a study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.","longName":"PHASE_II_TR_RECOM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2422281","version":"1","preferredName":"Phase II Trial","preferredDefinition":"A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.","longName":"C15601","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase II Trial","conceptCode":"C15601","definition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0380E320-F578-5E13-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-10-20","modifiedBy":"ONEDATA","dateModified":"2005-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224050","version":"1","preferredName":"Recommendation","preferredDefinition":"Advice telling someone what the best thing to do is.","longName":"C25197","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recommendation","conceptCode":"C25197","definition":"Advice telling someone what the best thing to do is.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F0876-209E-4F9B-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0380E320-F579-5E13-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-10-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2422686","version":"1","preferredName":"Phase II Agent Dose","preferredDefinition":"the quantity of an agent or drug in a Phase II Trial.","longName":"PHASE_II_AGT_DOSE","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":"3","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207920","version":"1","preferredName":"Agent Dose","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The amount of medicine taken, or radiation given, at one time.","longName":"C1708:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-353A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-AC49-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-10-24","modifiedBy":"PWEST","dateModified":"2006-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812446","version":"1","longName":"Clinical Data Update System","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000130","version":"1","longName":"Clinical Data Update System","context":"CTEP"},{"publicId":"2812622","version":"1","longName":"Phase 1 End Point","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Recommended Phase 2 Dose or M","type":"Preferred Question Text","description":"Recommended Phase 2 Dose or Minimum Effective Dose","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2.","url":"http://ctep.cancer.gov/reporting/cdus.html","context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"0380E320-F58B-5E13-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-10-20","modifiedBy":"HARTLEYG","dateModified":"2017-04-05","changeDescription":"05/11/16 Moved to NRDS context as part of NRDS Standardization WG; 04/05/17 Moved to NCIP due to change in scope of NRDS program\r\n","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}